Ask AI

Improving Outcomes With Oral SERDs in MBC: Case Challenges and Skill-Building Strategies for the Advanced Practice Provider

Slideset

Released: September 17, 2026

See Activity Collection

Downloadable slides on the evolving role of oral next-generation estrogen receptor (ER)–directed therapies in ER-positive/HER2-negative metastatic breast cancer (MBC). The slides review mechanisms of endocrine resistance, the clinical significance of acquired ESR1 mutations, and strategies for genomic and ctDNA testing, including when to test, how to interpret results, and when additional pathology input may be needed. Key clinical trial data for oral SERDs and other ER-directed therapies, including elacestrant, imlunestrant, camizestrant, and vepdegestrant, are presented alongside guidance on treatment selection, adverse event recognition and management, dose modifications, drug interactions, monitoring, patient counseling, and adherence. Together, these topics support APPs in translating biomarker and efficacy data into individualized treatment decisions while helping patients navigate the practical and safety considerations of oral endocrine therapy.

Oral SERDs in MBC

Activity Information

Released: September 17, 2026